Dr. Marc J. Kahn

Request as Speaker

Request as Media Expert

Chief of Hematology, Department of Internal Medicine

Expertise: Medicine, Hematology, Oncology, Health education, Business of medicine

Biography

Dr. Marc J. Kahn is chief of hematology at the Kirk Kerkorian School of Medicine's Department of Internal Medicine. He is a prolific researcher in benign hematology, medical education, and healthcare finance.

He has served in leadership roles with the Association of American Medical Colleges, American College of Physicians, American Society of Hematology, National Board of Medical Examiners, and the National Residency Matching Program.

Dr. Kahn has authored over 100 peer-reviewed manuscripts in addition to 110 book chapters and five textbooks. In 2020, his most recent textbook, “Business Basics of Building and Managing a Healthcare Practice,” was published by Springer Nature.

He formerly served as vice president for health affairs at UNLV and as dean of the university's medical school — developing curricula, clinical programs, and research to elevate healthcare in the region. Prior to joining UNLV in April 2020, Dr. Kahn was a senior associate dean at Tulane University School of Medicine.

Education

M.D., University of Pennsylvania School of Medicine
M.B.A., Tulane University
B.A., Chemistry, University of Pennsylvania

Search For Other Experts On

health & medicine

Dr. Marc J. Kahn In The News

New study links sleep consistency to long-term health, Dr. Marc Kahn weighs in

A new study suggests sleep quality and consistency may be linked to long-term health. Researchers analyzed wrist-tracker data from more than 95,000 people and found that six to eight hours of sleep was associated with the lowest health risk across many conditions.

UNLV doctor shares warning as fourth death linked to measles in Pennsylvania

A fourth death has been linked to measles in Pennsylvania and a UNLV doctor is sounding the alarm.

Dr. Kahn joins ARC Las Vegas to discuss AI-designed drug and aging research

Researchers are studying whether a drug designed with artificial intelligence could help people live healthier, longer lives. The experimental drug was originally developed to treat people with idiopathic pulmonary fibrosis, a serious lung disease that causes scarring and breathing problems.

New pancreatic cancer drug offers hope but raises access questions with a hefty price tag

A newly approved pancreatic cancer drug is offering new hope for some patients, but its nearly half-million-dollar price tag is raising questions about who will be able to access it and how families might afford it.